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Introduction
Drug-induced movement disorders include drug-induced parkin-
sonism (DIP), tardive dyskinesia (TD), tardive dystonia, akathisia, 
myoclonus, and tremor. Among these, DIP is the most common 
movement disorder induced by drugs that affect dopamine re-
ceptors.
1-3 Since the clinical manifestations of DIP are very sim-
ilar to those of Parkinson’s disease (PD), patients with DIP are 
frequently misdiagnosed as having PD.
1,4 These patients are of-
ten prescribed antiparkinsonian drugs unnecessarily for long 
periods of time, despite recovery being possible simply by dis-
continuing the offending drugs. Dopamine transporter (DAT) im-
aging may be used in the differential diagnosis of various eti-
ologies of parkinsonism, including DIP.
5,6 The aim of this review 
was to provide clinicians with updated information about the 
clinical characteristics and DAT imaging findings of patients 
with DIP, and about the correct treatment for DIP.
Epidemiology of Drug-Induced 
Parkinsonism
The exact prevalence and incidence of DIP are unclear be-
cause it is frequently unrecognized or misdiagnosed as PD. The 
first study of the extrapyramidal side effects (EPS) of the anti-
psychotic chlorpromazine found that about 40% of these pa-
tients exhibited parkinsonism,
7 and several subsequent epide-
miological studies found that DIP is the second most common 
etiology of parkinsonism.
8-10 A community-based survey and a 
population-based study found DIP prevalence rates of 2.7% and 
1.7%, respectively, whereas those of PD were 3.3% and 4.5%, 
respectively.
8-10 However, 6.8% of the patients diagnosed with 
PD were later reclassified as having DIP, thus emphasizing the 
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difficulties in accurately diagnosing DIP and in measuring its 
prevalence.
4 Age is the most obvious risk factor for DIP,
11-13 
since dopamine concentrations decrease and nigral cells degen-
erate with age.
14 Another risk factor is female gender,
8,15-17 sug-
gesting that estrogen suppresses the expression of dopamine 
receptors;18 however, the exact mechanism underlying the gen-
der difference in DIP remains to be clarified. Genetic factors 
are also thought to be involved in the development of DIP be-
cause not all patients taking dopamine receptor blocking agents 
(DRBAs) develop parkinsonism.
19-21 Genome-wide screening 
showed that the genes associated with the gamma-aminobu-
tyric acid (GABA) receptor signaling pathway are involved in 
neuroleptic-induced TD in schizophrenic patients,
21 suggesting 
that genetic factors predispose to both DIP and TD.
Etiology of Drug-Induced 
Parkinsonism
Typical antipsychotics, also known as neuroleptics, are the most 
common causes of DIP. However, atypical antipsychotics, which 
were thought to be free from EPS, can also induce parkinson-
ism. In addition to antipsychotics, gastrointestinal (GI) motility 
drugs, calcium channel blockers (CCBs), and antiepileptic 
drugs have been found to induce DIP (Table 1).
 
Antipsychotic drugs
The history of DIP parallels that of antipsychotics. Parkinson-
ism as a side effect of chlorpromazine was first reported 3 
years after its introduction.
7 It was soon recognized that all typ-
ical antipsychotics had the potential to cause EPS, including 
parkinsonism, acute dystonia, akathisia, and TD.
7,22,23 Typical 
antipsychotics include chlorpromazine, promazine, haloperi-
dol, perphenazine, fluphenazine, and pimozide. About 80% of 
patients taking typical antipsychotic drugs exhibit more than 
one kind of EPS.
24 Dopamine receptors are widely distributed 
in the brain, and typical antipsychotics may act on dopamine 
receptors in the striatum. Therefore, all patients taking antipsy-
chotics have some risk of developing parkinsonism and other 
EPS. Parkinsonism usually appears days to weeks after starting 
antipsychotics, but in rare cases the onset delay may be several 
months or more. The risk of EPS was thought to be low for atypi-
cal antipsychotics. Atypical antipsychotics include clozapine, 
risperidone, olanzapine, quetiapine, and aripiprazole. It was orig-
inally thought that their relatively low frequency of associated 
EPS was due to them being more strongly antagonistic toward 
serotonin-2A receptors than toward dopamine receptors.
25-27 
This serotonin-dopamine hypothesis has long been considered 
a useful model for developing atypical antipsychotics that ex-
hibit superior antipsychotic efficacy with a lower incidence of 
EPS compared to typical antipsychotics.
25-27 The recent ‘fast-
off’ theory suggested that their rapid dissociation from D2 re-
ceptors after they have blocked them can explain their lower 
risk of EPS.
28,29
In 1989, clozapine became the first atypical antipsychotic 
drug to be approved by the US Food and Drug Administra-
tion.
26 It is effective in schizophrenia patients with drug-resis-
tant negative symptoms, with an almost complete absence of 
EPS. DIP due to clozapine has not been reported, and it was 
found to improve psychosis without aggravating parkinsonism 
even in PD patients.
30 However, clozapine has been associated 
with agranulocytosis in about 1% of patients, making physi-
cians reluctant to prescribe this drug. Other atypical antipsy-
chotics without the risk of agranulocytosis were developed to 
control psychosis with minimal EPS. Risperidone was expect-
ed to have a minimal risk of EPS because it has a high affinity 
for serotonin receptors.
31 However, it binds D2 receptors in a 
dose-dependent manner, thus inducing parkinsonism and EPS 
to a similar extent as high doses of typical antipsychotics.
31 Al-
though the molecular structure of olanzapine is similar to that 
of clozapine, it carries with it a significant risk of EPS.
32 Que-
tiapine is an atypical antipsychotic with a low risk of EPS and 
a low risk of aggravation of parkinsonism when used to treat 
psychotic symptoms in patients with PD, and is therefore ap-
parently safe for use in elderly patients.
33,34 Aripiprazole is the 
Table 1. Common offending drugs of drug-induced parkinsonism
Drug frequently causing parkinsonism Drug infrequently causing parkinsonism
Typical antipsychotics Phenothiazine: chlorpromazine, prochlorperazine,
  perphenazine, fluphenazine, promethazine
Atypical antipsychotics Clozapine, quetiapine
Butyrophenones: haloperidol
Diphenylbutylpiperidine: pimozide Mood stabilizer Lithium
Benzamide substitutes: sulpiride
Atypical antipsychotics  Risperidone, olanzapine, 
  ziprasidone, aripiprazole
Antidepressant SSRI: citalopram, fluoxetine,
  praoxetine, sertraline
Dopamine depleters Reserpine, tetrabenazine Antiepileptic drugs Valproic acid, phenytoin
Antiemetics Metoclopramide, levosulpiride, clebopride Antiemetics Domperidone, itopride
Calcium-channel blocker Flunarizine, cinnarizine
SSRI: selective serotonin reuptake inhibitor.Shin HW and Chung SJ
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most recently introduced novel atypical antipsychotic, and has 
a unique mechanism of action. Although it was expected to have 
a low risk of EPS, clinical experiences have been disappoint-
ing.
35,36 Thus, to date, only clozapine and quetiapine are asso-
ciated with low rates of DIP in older patients.
 
GI motility drugs
GI prokinetic drugs, including metoclopramide, levosulpiride, 
clebopride, itopride, and domperidone, have also been associ-
ated with DIP. These drugs have been used clinically to man-
age motor disorders of the upper GI tract, including functional 
dyspepsia and emesis. The prokinetic effect of these drugs is 
mediated through their blockade of enteric inhibitory D2 re-
ceptors.
37 Besides binding to receptors in the peripheral end or-
gans, thus inducing antiemetic effects via D2 receptor blockade 
in the area postrema, they also antagonize central D2 receptors, 
leading to adverse effects including hyperprolactinemia and 
EPS. All prokinetics with D2-receptor-antagonizing properties 
have been found to induce EPS, although the extent of symp-
toms varies. Among the GI prokinetics, metoclopramide is the 
most-well-known cause of drug-induced movement disor-
ders.
17,38-40 Furthermore, levosulpiride is used widely in several 
Asian and European countries to treat nausea, vomiting, and 
functional dyspepsia. Until recently, the drug-induced move-
ment disorders related to levosulpiride were under-recognized, 
but it has now been shown that levosulpiride frequently causes 
parkinsonism.
41 Whereas metoclopramide usually induces TD, 
levosulpiride causes parkinsonism more frequently than TD or 
other EPS. Although metoclopramide and levosulpiride have 
the same mechanism of action, they show different patterns 
of adverse effects, the reason for which remains to be clarified. 
In general, domperidone is considered to be safe for the man-
agement of GI discomfort, even in patients with PD, because 
it does not cross the blood-brain barrier.
37 However, although 
rare, acute dystonic reactions to this drug may occur.
42
Other drugs
Parkinsonism may also be caused by CCBs, antiepileptic drugs, 
and lithium, although their exact pathophysiological mecha-
nisms are not yet known. CCBs including flunarizine and cin-
narizine, which are used to control dizziness and headache,
43 
may cause DIP by reducing dopamine neurotransmission or act-
ing directly on dopamine receptors.
44-47 The long-term use of 
valproic acid was found to induce parkinsonism in 5% of pa-
tients;48-50 while the exact underlying pathophysiology has not 
been clarified, one suggestion is that it is due to oxidative stress 
and mitochondrial dysfunction.
50 Lithium is an infrequent cause 
of DIP and is thought to act by decreasing dopamine in the stri-
atum, or as an anticholinesterase that increases central cholin-
ergic activity.
51,52
Clinical Characteristics  
of Drug-Induced Parkinsonism
DIP is generally characterized clinically as bilateral and sym-
metric parkinsonism, with more prominent bradykinesia and ri-
gidity than in patients with PD.
13,53 However, it has been sug-
gested in many studies that clinical manifestations alone cannot 
be used to differentiate DIP from PD (Table 2). 
Typically 30-50% of patients with DIP show asymmetric 
parkinsonism and tremor at rest; these characteristics are con-
sidered to support a PD diagnosis.
16,41,44,45,54 Interestingly, DIP 
patients with typical tremor at rest tremors usually also have 
postural tremors. The similar clinical manifestations of DIP and 
PD indicate that patients with DIP may have been in a preclini-
cal stage of PD and that their parkinsonism may have been un-
masked by the offending drugs. This is supported by findings 
that parkinsonism persists or even progresses after cessation of 
the drug in many DIP patients.
17,38,40,41,45 In a long-term follow-
up study, parkinsonism reappeared several months after the 
complete resolution from DIP in 7% of patients;41 DIP might 
have anteceded PD in those patients. 
The mean age at symptom onset is greater for DIP than for 
PD patients. In addition, DIP is more common in females, wh-
ereas males are more likely to have PD. While the duration of 
symptoms is similar, neurological deficits are more severe in 
Table 2. Clinical characteristics of drug-induced parkinsonism
Drug
Mean 
age
Gender
Asymmetric parkinsonism 
(percentage 
of number of patients)
Tremor (percentage 
of number of patients)
Combined TD 
(percentage of 
number of patients)
Hardie et al.16  Antipsychotics 61 F>M 44 Not described 42
Hassin-Baer et al.54  Antipsychotics 46 F<M 41 Rest tremor (44%) 45
García-Ruiz et al.44 Calcium channel 
blocker
71 F>M 36 Postural tremor
Rest tremor
Not described
Martí-Massó et al.45  Cinnarizine 75 F>M 13 Postural tremor (51%) 7
Shin et al.41 Levosulpiride 70 F>M 38 Rest tremor (45%)
Postural tremor (53%)
7
F: female, M: male, TD: tardive dyskinesia.Drug-Induced Parkinsonism
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DIP than in PD. Orolingual dyskinesia in drug-naïve PD pa-
tients is rare, whereas it is frequently combined with parkinson-
ism in DIP patients. The symmetry and type of tremor are not 
useful in distinguishing DIP from PD.
Pathophysiology of Drug-Induced 
Parkinsonism
Dopamine receptors in the brain consist of those of the D1 
family, comprising D1 and D5 receptors, and the D2 family, com-
prising D2, D3, and D4 receptors.
55 The central dopaminergic 
system consists of the mesolimbic, mesocortical, tuberoinfun-
dibular, and nigrostriatal pathways. All antipsychotic drugs have 
potent D2 receptor blocking capacity and the therapeutic effects 
of these drugs on psychosis are related to their action on the 
limbic system, where they reduce dopamine transmission. The 
blockage of D2 receptors by antipsychotic drugs in the stria-
tum leads to disinhibition of GABA- and encephalin-contain-
ing striatal neurons at the origin of the indirect pathway with-
out alteration of the direct pathway, followed by disinhibition 
of the subthalamic nucleus. This leads to increased GABAer-
gic inhibition of the thalamocortical projection by facilitation 
of the inhibitory projection from the globus pallidus/substantia 
nigra pars reticulata (Fig. 1A). This pathway resembles the mod-
el of disturbance of the basal ganglia-motor loop in PD. More 
than 80% of D2 receptors were found to be occupied in patients 
with EPS who were taking neuroleptics,
56 in agreement with 
results showing that clinical symptoms of PD began when over 
80% of nigral neurons had degenerated.
TD, defined as hyperkinetic movement in the orolingual or 
oromandibular area, is caused by long-term use of dopaminer-
gic blocking agents, and frequently accompanies DIP. The co-
occurrence of TD with parkinsonism may be due to dopami-
nergic receptor supersensitivity resulting from long-term D2 
receptor blocking. Chronic administration of these drugs in-
creases dopamine D2 receptor density in the striatum. Moreover, 
withdrawal from neuroleptics was found to aggravate dyski-
netic symptoms, whereas increased doses of neuroleptics tran-
siently suppressed dyskinesia. D1 receptors may also be in-
volved in the development of orolingual dyskinesia when D2 
receptors are chronically blocked. Chronic administration of 
D2 receptor blockers also induces changes in the direct path-
way of the basal ganglia-motor loop to activate the striatoni-
gral pathway and increase the inhibition of the striatopallidal 
pathway (Fig. 1B).
25,57 This imbalance between direct (D1) and 
indirect (D2) motor pathways and the resulting alterations in 
the globus pallidus/substantia nigra pars reticulata complex 
may lead to hyperkinetic orolingual movements, thus explain-
ing the coexistent and sequential development of parkinson-
ism and dyskinesia.
 
Diagnosis of DIP and the Role 
of DAT Imaging
The clinical diagnostic criteria for DIP are defined as 1) the 
presence of parkinsonism, 2) no history of parkinsonism before 
the use of the offending drug, and 3) onset of parkinsonian 
symptoms during use of the offending drug. Since asymmetri-
cal rest tremors are common in many DIP patients and symp-
toms persist or progress after cessation of the offending drug, 
patients clinically diagnosed with DIP may include individuals 
in the preclinical stage of PD whose symptoms were unmasked 
Parkinsonism
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Fig. 1. Changes in basal ganglia-thala-
mocortical motor loop due to blockade 
of D2 receptors by DRBAs. The block-
age of D2 receptors by DRBAs in the 
striatum leads to disinhibition of GABA- 
and encephalin-containing striatal neu-
rons at the origin of the indirect path-
way, followed by a disinhibition of the 
subthalamic nucleus. This leads to in-
creased GABAergic inhibition of the 
thalamocortical projection by facilitation 
of the inhibitory projection from the 
GPi/SNr (A). Chronic D2 receptor block-
ade also induces changes in the direct 
pathways of the basal ganglia-motor 
loop to cause orolingual dyskinesia (B).   
DA: dopamine, DRBAs: dopamine re-
ceptor blocking agents, GABA: gamma-
aminobutyrik acid, GPe: globus pallidus 
pars externa, GPi: globus pallidus pars 
internal, SNc: substantia nigra pars com-
pacta, SNr: substantia nigra pars reticu-
lata, STN: subthalamic nucleus, TD: 
tardive dyskinesia.Shin HW and Chung SJ
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by the drug.
15,41,58,59
DATs are presynaptic proteins in the membrane on terminals 
of dopaminergic neurons. They take up dopamine from the syn-
aptic cleft projections that extend from the substantia nigra to 
the striatum. These transporters control dopaminergic transmis-
sion by spatial and temporal buffering, rendering the molecule 
an imaging target in diseases affecting the dopaminergic nigros-
triatal pathway. Single-photon-emission computed tomography 
(SPECT) and positron-emission tomography (PET) scans are 
available using several DAT ligands.
6,60 SPECT radioligands 
include 
123I-N-3-fluoropropyl-2β-carbomethoxy-3β-(4-
iodophenyl)nortropane (123I-FP-CIT or 
123I-β-CIT-FP), 
123I-
ioflupane, DaTSCAN, and 
123I-2β-carbomethoxy-3β-(4-
iodophenyl)tropane (123I-β-CIT).
61 PET scans may be superior 
to SPECT for imaging DATs, in that the lower energy of posi-
trons provides higher resolution, resulting in better image qual-
ity with widespread clinical applications.
60 However, most 
DAT imaging studies, including those in patients with DIP, 
have utilized SPECT.
53,62-64
DAT uptake in the striatum is significantly decreased in PD 
patients, even during the early stages of the disease, because 
the motor symptoms of PD do not appear until 60-80% of do-
paminergic neurons degenerate.
65 In addition, drugs causing 
parkinsonism, such as DRBAs, have negligible affinity for 
DAT.
66,67 DAT scans may show symmetric uptake of radiotrac-
er in the bilateral striatum in patients with pure DIP, even if 
they have significant parkinsonism (Fig. 2A). PD can be diag-
nosed in DIP patients whose DAT uptake decreases asymmet-
rically in the striatum (Fig. 2B). Therefore, DAT scans may be 
useful for differentiating PD unmasked by drugs from pure 
DIP. Follow-up DAT scans of DIP patients with initially nor-
mal DAT scans exhibited normal uptake in the striatum, where-
as scans of patients with initially decreased DAT scans in the 
striatum exhibited progressive reduction of striatal tracer up-
take.
62 These findings suggest that DAT imaging provides use-
ful information for diagnosing DIP and may help in the design 
of a therapeutic plan. Further studies involving larger numbers 
of patients are needed to determine the sensitivity and speci-
ficity of DAT scans in DIP diagnosis.
Treatments and Outcomes of DIP
DIP is generally treated by cessation of the offending drugs. 
Patients who cannot stop taking antipsychotic drugs because 
of their psychiatric diseases, such as those with schizophrenia 
or major depressive disorders, may be switched to atypical an-
tipsychotics that have a lower risk of EPS. People who are pre-
scribed dopamine antagonists due to simple GI disturbance, 
headache, dizziness, or insomnia should stop taking the offend-
ing drugs as soon as possible. Anticholinergics including tri-
hexyphenidyl, benztropine, amantadine, and levodopa have 
been empirically tested for their ability to relieve symptoms of 
DIP, but this has produced no clear evidence of their effects in 
DIP patients.
3,16,54,68,69
DIP usually resolves within weeks to months after stopping 
the offending drug; however, parkinsonism may persist or 
progress in 10-50% of patients. The prognosis of patients with 
DIP can be classified into the following types: 1) full and long-
lasting recovery from DIP with no subsequent development 
of parkinsonism, 2) persistence but not progression of parkin-
sonism, 3) persistence and eventual worsening of parkinson-
ism, and 4) full remission of parkinsonism but later reappear-
ance after discontinuation of the offending drug. Only patients 
classified as type 1 can be defined as having ‘pure DIP’, where-
as those classified as type 3 or 4 may be in the preclinical stag-
es of PD.
67 The finding of Lewy bodies in two DIP patients 
who had completely recovered after stopping the offending 
drugs
70 suggests that clinical course alone cannot distinguish 
‘pure DIP’ among patients clinically diagnosed with DIP. In 
DIP patients classified as type 2, the persistence of parkinson-
ism may be due to permanent DRBA-induced damage to do-
pamine receptors.
71,72 DAT imaging may be useful in diagnos-
ing DIP patients and predicting their clinical course. A large 
prospective study may provide more information on the exact 
prognosis and factors related to recovery in DIP patients.
Conclusions
DIP is important because it is a common etiology of parkinson-
ism and is frequently either unrecognized or misdiagnosed as 
PD. In addition, parkinsonism in DIP patients is sufficiently se-
vere to affect daily activities and may persist for long periods 
of time even after cessation of the offending drug. DAT imag-
ing may be useful for accurately diagnosing patients with DIP 
A   B  
Fig. 2. 
123I-FP-CIT PET imaging in two DIP patients. DAT uptake 
was normal and symmetric in the bilateral striatum in a pure DIP 
patient (A), whereas it decreased severely in the right striatum in 
a patient who was diagnosed with PD unmasked by DRBAs (B). 
DAT: dopamine transpoter, DIP: drug-induced parkinsonism, DRBA: 
dopamine receptor blocking agents, PD: Parkinson’s disease.Drug-Induced Parkinsonism
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and may help to identify the clinical characteristics and exact 
prognosis of this disorder.
About 50% of patients with DIP and other movement disor-
ders are treated with DRBAs for conditions unrelated to psy-
chosis, including depression, GI disturbance, anxiety, and in-
somnia.
1 Physicians should avoid prescribing DRBAs and 
CCBs for inappropriate reasons such as anxiety, insomnia, diz-
ziness or dyspepsia in elderly patients and should monitor these 
patients’ neurological signs, especially parkinsonism and other 
movement disorders, when prescribing these drugs.
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